Phenylacetylglycine
|
Basic information |
| Metabolite name | Phenylacetylglycine |
 | HMDB0000821 |
 |
C05598 |
 |
68144 |
| Synonyms | Phenacetylglycine; |
| No. of studies | 30 |
|
Basic information |
| Metabolite name | Phenylacetylglycine |
| HMDB0000821 |
|
C05598 |
|
68144 |
| Synonyms | Phenacetylglycine; |
| No. of studies | 30 |
|
Relationship between Phenylacetylglycine and depression (count: 30) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Up |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Up |
| Study M078 | Type1 | CORT model group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M088 | Type3 | 6-h venlafaxine group vs. control group | Urine | Wistar rat | Down |
| Study M095 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M095 | Type2 | CUMS + XCHT group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Amygdala | Cynomolgus monkey | Down |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M136 | Type2 | CUMS + high dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M136 | Type2 | CUMS + moderate dose of ZZHPD group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Urine | Human | Unknown |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M672 | Type2 | SMG + Hemerocallis citrina extracts group vs. SMG group | Urine | Sprague-Dawley rat | Up |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M689 | Type2 | CUMS + Danzhi Xiaoyao Powder group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Plasma | Sprague-Dawley rat | Unknown |
| Study M894 | Type1 | electromagnetic field exposure group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |